ARS Pharmaceuticals, Inc. (SPRY)
4.24
-0.32
(-7.02%)
USD |
NASDAQ |
Oct 09, 16:00
4.24
0.00 (0.00%)
After-Hours: 16:54
ARS Pharmaceuticals Gross Profit Margin (Quarterly) : 61.83% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 61.83% |
| March 31, 2026 | 72.29% |
| December 31, 2025 | 78.09% |
| September 30, 2025 | 74.80% |
| June 30, 2025 | 68.29% |
| March 31, 2025 | 82.77% |
| December 31, 2024 | 98.82% |
| September 30, 2024 | 93.57% |
| June 30, 2024 | 96.40% |
| Date | Value |
|---|---|
| March 31, 2024 | |
| December 31, 2023 | |
| September 30, 2023 | |
| June 30, 2023 | -100.0% |
| March 31, 2023 | 0.00% |
| December 31, 2022 | 0.00% |
| September 30, 2022 | 96.30% |
| June 30, 2022 | -105.2% |
| March 31, 2022 | 92.46% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Capricor Therapeutics, Inc. | -- |
| Sionna Therapeutics, Inc. | -- |
| Nektar Therapeutics | 98.46% |
| Vertex Pharmaceuticals, Inc. | 85.37% |
| Ardelyx, Inc. | 94.74% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -204.0% |
| Return on Assets | -69.45% |
| Return on Invested Capital | -117.4% |
| Profit Margin (Quarterly) | -185.2% |
| Operating Margin (Quarterly) | -182.6% |
| Return on Net Operating Assets | -360.9% |